Pharmacokinetics of Insulin Detemir in Healthy Volunteers From Taiwan
- Registration Number
- NCT01497587
- Lead Sponsor
- Novo Nordisk A/S
- Brief Summary
This trial is conducted in Asia. The aim of this trial is to investigate pharmacokinetics of insulin detemir in healthy Taiwanese subjects.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 20
Inclusion Criteria
- Considered generally healthy upon completion of medical history and physical examination as judged by the investigator
- Body mass index (BMI) between 18 and 27 kg/m^2, inclusive
- Fasting plasma glucose maximum 6.1 mmol/l
- Non-smoker or smoking maximum 5 cigarettes per day or the equivalent
Exclusion Criteria
- Participation in any other clinical trial involving other investigational products within the last 3 months
- Subject with a history of alcohol or drug dependence
- Subject with a first-degree relative with diabetes mellitus
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Insulin detemir insulin detemir -
- Primary Outcome Measures
Name Time Method Area under the insulin detemir concentration curve
- Secondary Outcome Measures
Name Time Method Maximum insulin detemir concentration Time to maximum insulin detemir concentration Insulin detemir half-life The mean residence time of insulin detemir
Trial Locations
- Locations (1)
Novo Nordisk Investigational Site
🇨🇳Taipei, Taiwan